Ionis Pharmaceuticals IONS Investments - Amortized Cost Basis
Investments - Amortized Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's investments - amortized cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's investments - amortized cost basis?
- Ionis Pharmaceuticals (IONS) reported investments - amortized cost basis of $1.75B in Q1 2026.
- How has Ionis Pharmaceuticals's investments - amortized cost basis changed year-over-year?
- Ionis Pharmaceuticals's investments - amortized cost basis decreased by 8.6% year-over-year, from $1.91B to $1.75B.
- What is the long-term trend for Ionis Pharmaceuticals's investments - amortized cost basis?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's investments - amortized cost basis has grown at a 17.1% compound annual growth rate (CAGR), from $1.25B to $2.35B.